The 30-Month Stay: How Patent Litigation Blocks Generic Drug Approval

Imagine you’ve spent years developing a cheaper version of a life-saving medication. The science is done. The safety data is solid. You submit your application to the U.S. Food and Drug Administration (FDA). But then, nothing happens for two and a half years. No rejection. No approval. Just silence. This isn’t bureaucracy gone wrong-it’s a feature of the system designed by law.

This delay is known as the 30-month stay, a regulatory pause triggered when brand-name drug makers sue generic challengers over patents. It is one of the most powerful tools in the pharmaceutical industry for delaying competition. While intended to balance innovation with access, many experts argue it has become a shield that keeps prices high long after drugs should be affordable.

How the 30-Month Stay Works

To understand why generic drugs face such delays, we need to look at the Hatch-Waxman Act, formally known as the Drug Price Competition and Patent Term Restoration Act of 1984. Signed into law by President Ronald Reagan, this legislation created a pathway for generic manufacturers to enter the market without repeating costly clinical trials. Instead, they file an Abbreviated New Drug Application (ANDA) proving their product is bioequivalent to the brand-name original.

However, the act also protected innovator companies. If a generic maker believes the brand’s patents are invalid or won’t be infringed, they can file what is called a Paragraph IV certification. This tells the FDA and the brand company: “We think your patent doesn’t stop us.”

Here is where the clock starts ticking. Once the brand company receives this notice, they have 45 days to decide whether to sue. If they file a lawsuit claiming patent infringement, the FDA is legally barred from approving the generic drug for up to 30 months. This automatic pause is the 30-month stay.

The logic behind this rule was simple: give both sides time to resolve legal disputes before the government approves a competitor. In practice, however, it often means consumers wait years longer for lower-cost options. According to a 2021 study published in Clinical and Translational Science by researchers from the University of Southern California and the University of Michigan, the stay begins on the date the last recipient of the Paragraph IV notice receives it. Courts can shorten this period if litigation resolves quickly, but they cannot extend it beyond 30 months unless specific exceptions apply.

Why the Delay Matters More Than You Think

You might assume that once the 30 months are up, the generic drug hits the shelves immediately. That is rarely the case. The FDA allows something called tentative approval during the stay. This means the agency has already reviewed the science and deemed the generic safe and effective-but it cannot finalize approval until the legal battle ends or the stay expires.

In 2022, the FDA processed 1,046 ANDAs, and 78% received tentative approval while patent litigation was ongoing. So why do generics still take so long to reach patients? Because commercial readiness matters just as much as regulatory clearance. A senior regulatory affairs specialist at Teva Pharmaceuticals noted on the Generics Bulletin Board forum that litigation often drags on past 30 months, but internal issues like manufacturing setup or supply chain logistics cause further delays.

Moreover, the 30-month stay interacts with other forms of protection. For New Chemical Entity (NCE) products-which qualify for five years of regulatory exclusivity-the effective delay can stretch to nearly 40 months. As explained in Axinn, Veltrop & Harkrider LLP’s 2022 Hatch-Waxman Overview, these overlapping protections create a formidable barrier to entry.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) tried to limit abuse by restricting brand companies to only one 30-month stay per generic applicant. Before that, some firms would list multiple patents and trigger sequential stays, effectively blocking competition indefinitely. The MMA closed that loophole, but new strategies emerged.

The Real Cost of Waiting

Let’s talk money. The U.S. generic drug market was valued at $127.4 billion in 2022, according to IQVIA’s Mid-Year Review. These drugs make up 90% of all prescriptions filled but account for just 23% of total spending. Why? Because generics cost far less than brand names-often 80-85% less within the first year of entry, as reported by the Congressional Budget Office in 2022.

But here’s the catch: the 30-month stay adds billions in extra costs. The Federal Trade Commission (FTC) estimated in 2021 that patent litigation delays caused by this mechanism add approximately $13.9 billion annually to U.S. prescription drug expenses. That’s real money taken from households, insurers, and government programs like Medicare.

Dr. Aaron Kesselheim, Professor of Medicine at Harvard Medical School, put it bluntly in his 2021 JAMA study: “The 30-month stay has become a tool for brand-name manufacturers to systematically delay generic competition through strategic patent litigation, adding a median 1.8 years to market exclusivity periods for blockbuster drugs.”

On the flip side, former FDA Commissioner Scott Gottlieb defended the system in 2020 Senate testimony, calling it “a necessary balance” that has enabled over 12,000 generic approvals since 1984, saving consumers roughly $2.2 trillion. He argued that without patent protections, companies wouldn’t invest in risky research and development.

So who’s right? Both sides have valid points. But the numbers suggest the current system favors incumbents more than innovators.

Who Wins and Who Loses?

Not everyone suffers equally under the 30-month stay. Generic manufacturers compete fiercely to be the first to file a Paragraph IV certification. Why? Because the first successful challenger gets 180 days of marketing exclusivity-a huge financial incentive. According to FDA data from 2022, drugs with multiple Paragraph IV filers reach generic approval 8.2 months faster than those with single filers. Competition drives speed.

Yet even among generics, not all players are equal. The top five manufacturers-Teva, Viatris, Sandoz, Hikma, and Sun Pharma-control 45% of the market. Meanwhile, Chinese and Indian firms now submit 63% of all ANDAs, bringing global pressure to bear on pricing and timelines.

For brand companies, the 30-month stay offers predictability. They know exactly how long they’ll face no direct competition. But critics say this certainty comes at a steep price. A 2019 Brookings Institution study found that 67% of patents listed in the Orange Book for top-selling drugs were obtained after the initial New Drug Application (NDA) approval. This practice, known as “patent evergreening,” involves securing secondary patents on minor changes-like pill shape or dosage form-to extend protection artificially.

And let’s not forget biologics. Unlike small-molecule drugs covered by Hatch-Waxman, biologics fall under the Biologics Price Competition and Innovation Act (BPCIA), which grants 12 years of exclusivity without a direct equivalent to the 30-month stay. Biosimilars will grow from 3% to 12% of the biologics market by 2028, potentially reducing reliance on traditional generic pathways altogether.

Is Change Coming?

Yes-and soon. Lawmakers across party lines are pushing to reform the 30-month stay. The Affordable Prescriptions for Patients Act of 2023 (H.R. 1034/S. 351), introduced by Representatives Jan Schakowsky and Mike Gallagher, proposes cutting the stay from 30 to 18 months and preventing stays for secondary patents entirely.

The FTC echoed this sentiment in its 2022 policy statement, urging reforms to prevent misuse through “patent thickets”-dense clusters of overlapping patents designed to confuse and deter challengers. Brand companies now list an average of 8.3 patents per drug in the Orange Book, up from just 1.2 in 1995.

If the 30-month stay were eliminated completely, the USC research team predicts generic entry would accelerate by a median of 9.2 months for small-molecule drugs, potentially saving consumers $28 billion annually. But PhRMA warns that such changes could reduce biopharmaceutical R&D investment by $14 billion each year, possibly delaying 24-36 new molecular entities over a decade.

It’s a tough trade-off. Protect innovation versus ensure access. Reward risk versus reward efficiency. There’s no easy answer-but ignoring the problem isn’t an option either.

What Should You Do About It?

If you’re a patient, advocate for transparency. Ask your doctor or pharmacist why certain generics aren’t available yet. Push policymakers to support bills that shorten unnecessary delays. Support organizations fighting for affordable medicines.

If you work in pharma, prepare for change. Regulatory strategy teams must anticipate shorter windows for exclusivity. Invest in genuine innovation rather than defensive patenting. Build partnerships early with potential generic partners to smooth transitions.

For investors, watch legislative developments closely. Companies reliant on extended patent protection may see margin compression if reforms pass. Conversely, generic makers positioned to capitalize on accelerated launches could gain significant market share.